RECRUITING

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone Cohort B: Patients with response to prior abiraterone, defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response

Official Title

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Quick Facts

Study Start:2021-09-08
Study Completion:2025-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04986423

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Males age ≥ 18 years
  2. 2. Metastatic, castration-resistant, histologically confirmed prostate cancer
  3. 3. Surgical castration or continuous medical castration for ≥ 8 weeks prior to screening; serum testosterone \< 50 ng/dL confirmed within 4 weeks of first administration of study drug
  4. 4. Have progressed on prior abiraterone treatment by PCWG3 criteria
  5. 5. Patients who are not candidates for chemotherapy in the opinion of the investigator or patients who decline chemotherapy
  6. 6. Cohort A only - Patient must meet definition of poor responder to abiraterone by one of the following:
  7. 1. Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone
  8. 2. Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve a PSA50 response
  9. 7. Cohort B only - Patient must meet definition of responder to abiraterone by one of the following:
  10. 1. Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL
  11. 2. Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and PSA50 response
  12. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  1. 1. Any history of brain metastases, prior seizure, conditions predisposing to seizure activity
  2. 2. Have previously received an investigational BET inhibitor (including previous participation in this study or a study of ZEN003694)
  3. 3. Receipt of prior second-generation androgen receptor inhibitors (e.g. enzalutamide, apalutamide, darolutamide, proxalutamide). Receipt of first-generation AR antagonists (e.g. bicalutamide, nilutamide, flutamide) does not count towards this limit.
  4. 4. Have received prior chemotherapy in the metastatic castration-resistant setting (prior chemotherapy in the hormone-sensitive setting is allowed provided last dose was at least 6 months prior to first dose of study drug)
  5. 5. Have received prior systemic anti-cancer therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first administration of study drug
  6. 6. Have received exogenous administration of testosterone therapy since discontinuation of abiraterone.
  7. 7. Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study entry
  8. 8. Radiation therapy within 2 weeks of the first administration of study drug

Contacts and Locations

Study Contact

Zenith Study Team
CONTACT
587-390-7865
ZEN003694-201@zenithepigenetics.com

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94158
United States
Innovative Clinical Research Institute
Whittier, California, 90603
United States
Colorado Urology
Lakewood, Colorado, 80228
United States
BRCR Global
Plantation, Florida, 33322
United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, 70809
United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109
United States
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, 10065
United States
Messino Cancer Center
Asheville, North Carolina, 28806
United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Zenith Epigenetics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-08
Study Completion Date2025-06

Study Record Updates

Study Start Date2021-09-08
Study Completion Date2025-06

Terms related to this study

Keywords Provided by Researchers

  • mCRPC
  • ZEN003694
  • ZEN-3694
  • Bromodomain
  • BETi
  • Enzalutamide
  • Xtandi®

Additional Relevant MeSH Terms

  • Metastatic Castration-Resistant Prostate Cancer